Research programme: cancer therapeutics - Carrick Therapeutics/Evotec SE
Latest Information Update: 28 Nov 2020
Price :
$50 *
At a glance
- Originator Carrick Therapeutics
- Developer Carrick Therapeutics; Evotec SE
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Nov 2020 No recent reports of development identified for research development in Cancer in Germany
- 28 Nov 2020 No recent reports of development identified for research development in Cancer in Ireland
- 28 Nov 2020 No recent reports of development identified for research development in Cancer in United Kingdom